Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1500 | FX06 Wiki | 0.50 |
| drug1546 | Flexitouch Plus with Cellular Connectivity (FT-CC) Wiki | 0.50 |
| drug2276 | Magnetic Resonance Spectroscopy (MRS). Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013226 | Status Epilepticus NIH | 0.50 |
| D002543 | Cerebral Hemorrhage NIH | 0.50 |
| D013345 | Subarachnoid Hemorrhage NIH | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000072656 | Breast Cancer Lymphedema NIH | 0.50 |
| D008209 | Lymphedema NIH | 0.35 |
| D001930 | Brain Injuries, NIH | 0.28 |
| D006470 | Hemorrhage NIH | 0.25 |
| D001943 | Breast Neoplasms NIH | 0.20 |
| D009461 | Neurologic Manifestations NIH | 0.20 |
| D000070642 | Brain Injuries, Traumatic NIH | 0.17 |
| D020521 | Stroke NIH | 0.13 |
| D014947 | Wounds and Injuries NIH | 0.08 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.04 |
| D055371 | Acute Lung Injury NIH | 0.04 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.04 |
| D011014 | Pneumonia NIH | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002133 | Status epilepticus HPO | 0.50 |
| HP:0002138 | Subarachnoid hemorrhage HPO | 0.50 |
| HP:0001342 | Cerebral hemorrhage HPO | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001004 | Lymphedema HPO | 0.35 |
| HP:0003002 | Breast carcinoma HPO | 0.20 |
| HP:0001297 | Stroke HPO | 0.13 |
| HP:0002090 | Pneumonia HPO | 0.03 |
Navigate: Correlations HPO
There are 4 clinical trials
As the world faces COVID-19, the search for effective treatments against the disease and its complications has turned its gaze to drugs that are classically used in other infectious diseases. Some drugs are being examined for the recent evidence on its effects on viral replication and inflammation, one is Azithromycin, used to treat a wide variety of bacterial infections, Ivermectin, an anti-parasitic drug and the other is Cholecalciferol to increase serum concentration of 25-hydroxyvitamin D.
Description: Test for virus at day 1 and 14 from beginning of trial drug started
Measure: Viral clearance Time: 14 daysDescription: The duration of symptoms in days
Measure: Symptoms duration Time: 14 daysDescription: oxygen saturation
Measure: SpO2 Time: 14 daysDescription: Oxygen Saturation (SpO2)/Fraction of Inspired Oxygen (FiO2) Ratio
Measure: SpO2/FiO2 Time: 14 daysOpen controlled clinical trial. Hospitalized pediatric patients with COVID-19 will be included. Upon admission to hospital serum determination of vitamin D, interleukins, ferritin and Dimer D will be performed. Subsequently, randomization will be performed to identify which group the patient belongs. Adverse effects will be evaluated on a daily basis. Serum levels of interleukin (IL) -2, 6, 7,10, ferritin and dimer-D will be taken at the beginning of hospitalization and on the 7th day after admission. It will be recorded if the patient presents deterioration of the respiratory function that requires endotracheal intubation and / or admission to intensive care and / or if he dies, and at what time of hospitalization does this outcome occur. The study will culminate when the patient is discharged from hospitalization.
Description: Taken on admission of the patient to hospitalization (through venipuncture measured by an in-vitro diagnostic enzyme immunoassay (ELISA) for quantitative determination) and on day 7 of hospitalization.
Measure: INTERLEUKINS (IL-2,6,7,10) (pg/ml) Time: 7 daysDescription: Taken on admission of the patient to hospitalization (through venipuncture measured by an in-vitro diagnostic enzyme immunoassay (ELISA) for quantitative determination) and on day 7 of hospitalization.
Measure: FERRITIN (ng/ml) Time: 7 daysDescription: Taken on admission of the patient to hospitalization (through venipuncture measured by an in-vitro diagnostic enzyme immunoassay (ELISA) for quantitative determination) and on day 7 of hospitalization.
Measure: DIMER-D Time: 7 daysDescription: determination of 25-hydroxy-Vitamin D in human serum
Measure: Vitamin D (ng/ml) Time: the beginning and through study completion, an average of 21 daysIn a blinded randomized clinical trial, which will include health workers (doctors, residents, nurses, stretcher-bearers, technicians, hygiene and cleaning) who are members of the health teams that care for patients with COVID-19. Two groups will be formed: the Vitamin D group taking 4,000 IU orally daily for 30 days, the control group being given a placebo during the same time period. Participants will be adults, who have not had COVID-19 disease, and who sign the informed consent. At the beginning of the study anthropometric variables (weight, height, BMI) will be taken, the short medical history can be identified to identify comorbidities, and a fasting blood sample will be taken to determine changes in Vitamin D (25 (OH) Vitamin D), in addition to RT-PCR saliva samples, as well as detection of serum antibodies to determine whether or not they have SARS-CoV-2 disease. Participants will follow each other 45 days. Those with COVID-19 disease will be monitored frequently to determine the course of the disease. At the end of 45 days, new samples will be taken to determine levels of vitamin D and antibodies against SARS-Cov-2.
Description: cases confirmed by RT-PCR for SARS-CoV-2, or by antibody detection.
Measure: Number of Participants with COVID-19 Time: 45 daysDescription: participants who, having developed SARS-CoV-2 infection, require hospitalization for the same condition.
Measure: Number of Participants with hospitalization for COVID-19 Time: 45 daysDescription: Serum concentration of 25 (OH) vitamin D at the beginning and through study completion, an average of 45 days
Measure: Serum concentration of 25 (OH) vitamin D Time: the beginning and through study completion, an average of 45 daysPatients diagnosed of COVID-19 disease are randomized to receive a single dose of 100.000 IU of Cholecalciferol (Vitamin D arm) or no vitamin D (on top of the current medication used to treat COVID 19). Clinical, radiological and biochemical outcomes of COVID 19 disease as well as mortality are evaluated.
Description: Percentage of patients dying during hospitalization
Measure: Mortality Time: Time to death or hospital discharge in days (average 12 days)Description: Percentage of patients admitted to ICU and time in ICU
Measure: Admission to Intensive Care Unit (ICU) Time: Time from hospital admission to discharge in days (average 12 days)Description: Number of days from hospital admission to discharge
Measure: Time of hospitalization Time: Time of hospitalization in days (average 12 days)Description: Percentage of patients with symptoms after treatment (Cough, fever, headache, weakness, dyspnoea, anosmia, diarrhoea, ageusia, others ...)
Measure: Clinical changes Time: At the time of hospital admission and discharge (average 12 days)Description: Changes in the percentage of patients with radiological findings of pneumonia and severity
Measure: Radiological changes Time: At the time of hospital admission and discharge (average 12 days)Description: Calcidiol levels in ng/mL.
Measure: Calcidiol changes Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Description: C-reactive protein (CRP) in mg/L
Measure: Inflammation markers changes (CRP) Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Description: Interleukin-6 (IL-6) in pg/mL
Measure: Inflammation markers changes (IL-6) Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Description: Leucocytes in cells per liter
Measure: Inflammation markers changes (Leucocytes) Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Description: D-dimer in µg/mL
Measure: Inflammation markers changes (D-dimer) Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Description: Creatinine in mg/dL
Measure: General biochemical parameters changes (Creatinine) Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Description: Ferritin in µg/L
Measure: General biochemical parameters changes (Ferritin) Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Description: Bilirubin in mg/dL
Measure: General biochemical parameters changes (Bilirubin) Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Description: Albumin in g/dL
Measure: General biochemical parameters changes (Albumin) Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Description: Haemoglobin in g/dL
Measure: General biochemical parameters changes (Haemoglobin) Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Description: High density lipoprotein (HDL cholesterol) in mg/dL
Measure: General biochemical parameters changes (HDL cholesterol) Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Description: Procalcitonin in ng/mL
Measure: General biochemical parameters changes (Procalcitonin) Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Description: Protonin in ng/L
Measure: General biochemical parameters changes (Protonin) Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Description: Calcium in mg/dL
Measure: General biochemical parameters changes (Calcium) Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Description: Phosphate in mg/dL
Measure: General biochemical parameters changes (Phosphate) Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Description: pO2 in mmHg
Measure: General biochemical parameters changes (pO2) Time: At the time of hospital admission (before initiation of treatment) and at hospital discharge (average 12 days)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports